The National Bureau of Statistics reported a total of 10.41 million...
Category:
Health
Latest
First Indian intranasal Covid-19 vaccine to be launched on Jan 26
Earlier, Bharat Biotech had announced that it would sell the...
Study finds orienteering can train brain, help to fight cognitive decline
"Modern life may lack the specific cognitive and physical...
The Pandemic workday Is 48 minutes longer and has more meetings
The researchers compared employee behavior over two 8 week periods before and after Covid-19 lockdowns. Looking at email and meeting meta-data, the group calculated the workday lasted 48.5 minutes longer, the number of meetings increased about 13% and people sent an average of 1.4 more emails per day to their colleagues.
“People have adjusted their work patterns,” said Jeff Polzer, a professor in the organizational behavior department at Harvard Business School, one of the study’s five co-authors.
90% of recovered COVID-19 patients in Wuhan suffering from lung damage:report
According to the first phase results, 90 per cent of the patients” lungs are still in a damaged state, which means their lungs ventilation and gas exchange functions have not recovered to the level of healthy people, state-run Global Times reported.
Some recovered patients have to rely on oxygen machines even three months after being discharged from the hospital, Liang Tengxiao, a doctor from the Dongzhimen Hospital, Beijing University of Chinese Medicine, was quoted as saying by the report.
Let Ayushman Bharat guide states to fix the cost of Covid -19 treatment,Centre to SC
CJI Bobde asked the government to urge insurance companies to release dues promptly.
“When there is a pandemic, insurance companies cannot keep their hands off,” he said.
Indian pharma majors race ahead to launch affordable drugs for Covid-19 treatment
Drug major Cipla is working with government agencies to develop a treatment for COVID-19 while ramping up the production of various life saving essential drugs, according to company’s chairman YK Hamied.
Drug firm BDR Pharmaceuticals on Wednesday said it has launched its antiviral drug Favipiravir for the treatment of COVID-19 patients in India at a price of Rs 63 per tablet.
Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name ‘Covihalt’ for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.
COVID-19 tally rises to 18,55,745, recoveries cross 12-lakh mark in India
The death toll due to COVID-19 climbed to 38,938 with 803 fresh fatalities being reported in 24-hours, the data updated at 8 am showed.
A total of 12,30,509 people have recovered, while there are 5,86,298 active cases of coronavirus infection in the country presently.
The recovery rate among COVID-19 patients has risen to 66.31 per cent, while the fatality rate has further dropped to 2.10 pc, the data stated.
Disburse pension to elderly on time; provide PPE, face masks to people in old age homes:SC
A bench headed by Justice Ashok Bhushan said this while hearing a plea filed by former Union minister and senior advocate Ashwani Kumar who said that at the time of the pandemic, it is necessary that pension to elderly reaches them on time.
Kumar told the top court that crores of elderly people are living alone and appropriate direction should be issued that pension reaches to those, who are already identified and eligible for it, on time.
Are pharma companies are trying to profiteer from Covid-19 vaccines
If a vaccine proves too expensive or difficult to obtain, those who seek exorbitant profits off of it will be scrutinized far more closely than bankers were after the 2008 crash. Actions like those that have already allowed insiders to pocket $80 million will provoke public revulsion, even if those trades were pre-scheduled. Calls to regulate sectors that take for granted intellectual property protections will grow exponentially. Those demands won’t be fanatical or radical, but mainstream.
India ‘flying blind’, needs better data collection to control Covid-19
India’s death registration data was patchy even before the virus struck. The vast majority of deaths, especially in rural villages, take place at home and routinely go unregistered. For others the cause of death listed is often anodyne — old age or heart attack. Experts believe that only between 20 per cent-30 per cent of all deaths in India are properly medically certified.
AIA and Practo joins hands to promote consumer wellness in India
Bill Lisle, AIA Group Regional Chief Executive and Group Chief Distribution Officer, said, “This partnership is the outcome of AIA’s commitment to providing compelling, integrated and personalised propositions to our customers in India. Practo has an outstanding track record as India’s leading digital healthcare platform and we look forward to collaborating to benefit customers of both entities..Our partnership with Practo reflects our commitment to the Indian market and our confidence in its long-term prospects given the combination of strong economic growth, rising incomes and low insurance penetration.”
Aditya Birla Health Insurance launches Covid-19 cover
Mumbai: With the onset of COVID-19, Aditya Birla Health Insurance (ABHICL),the health insurance arm of Aditya Birla Capital Limited, has introduced an array of services and product solutions that will enable customers to take care of their health in such...